Appendix 1:

Characteristics of investigational drug product for clinical trial	
Current status (approved product)	Proposed status (drug product for new
	clinical trial)
1. Investigational product	
Active substance:	Active substance:
• Name	• Name
Structural formula	Structural formula
Manufacturer	Manufacturer
• Specification	• Specification
Finished product:	Finished product:
Name, dosage form, strength	Name, dosage form, strength
Complete composition	Complete composition
• Specification of excipients (e. g. reference	• Specification of excipients (e. g. reference
to Pharmacopoeia)	to Pharmacopoeia)
Manufacturer	Manufacturer
• Specification	Specification
• Container	• Container
• Shelf-life	• Shelf-life
2. Comparator product	
Data requested for comparator product are to be found in SÚKL guideline KLH-19. In case the comparator product was assessed in the past as well and the sponsor refers to already assessed clinical trial, the same data as for the investigational product are requested.	

(reference number of SÚKL) (number and date of approval – for	
biological/biotechnological product only)	
with the drug product	
no changes and variations to drug product quality and its manufacturing process were implemented.	
these changes and variations to drug product quality and its manufacturing process were implemented: (describe)	
no changes occured: 1) regarding TSE safety – for all material of animal origin 2) regarding virogogical safety of all material of human and animal origin	
**these changes and variations were implemented: 1) regarding TSE safety – for all material of animal origin: (describe) 2) regarding virogogical safety of the material of human and animal origin: (describe)	
Date, stamp and signature of responsible person of the sponsor:	
delete if not applicable delete if not applicable	